FDA approves Topamax for migraine prevention in adolescents

FDA approves Topamax for migraine prevention in adolescents

Today, the U.S. Food and Drug Administration approved Topamax (topiramate) for prevention (prophylaxis) of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group. The

7
Like
Save

Comments

Write a comment

*